ARKK vs COLL
ARK Innovation ETF (ARKK) versus Collegium Pharmaceutical Inc (COLL) — a side-by-side from cached financials, not a winner call.
ARK Innovation ETF (ARKK) common stock listed on US.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
ARKK does not have a complete income-statement cache yet.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
ARKK currently screens at market cap $0. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Not investment advice. Open the ARKK and COLL stock pages for the full models.
Not investment advice.